Humalog Mix Kwikpen75%+25%

Humalog Mix Kwikpen is a premixed biphasic insulin analog formulation indicated for the treatment of diabetes mellitus in patients who require insulin for control of hyperglycemia.

Established / FDA-approved uses

• Type 2 diabetes mellitus: Improve glycemic control in adults who require insulin therapy, typically after oral antidiabetic agents alone are inadequate. This is the primary approved use.
• Type 1 diabetes mellitus: As part of an insulin regimen for glycemic control, although Humalog Mix Kwikpen is generally less flexible than basal-bolus regimens because the intermediate-to-rapid-acting ratio is fixed.

Guideline-supported use

• Used as a twice-daily premixed insulin option in stepwise insulin intensification per diabetes management guidelines, generally in patients whose lifestyle favors a simpler fixed-ratio regimen over multiple daily basal-bolus injections.

Humalog Mix Kwikpen is not indicated for the treatment of diabetic ketoacidosis; a rapid-acting, short-duration intravenous insulin is preferred in that setting.

Insulin Lispro Protamine + Insulin Lispro is a sterile, premixed suspension for subcutaneous injection, available in fixed ratios that combine an intermediate-acting insulin (insulin lispro protamine suspension) with a rapid-acting insulin (insulin lispro solution), commonly supplied as 75%/25% or 50%/50% mixtures at a strength of 100 units/mL (U-100).

Each formulation of Insulin Lispro Protamine + Insulin Lispro also contains standard injectable excipients such as protamine sulfate, zinc oxide, metacresol, phenol, glycerin, and water for injection, with pH adjusted using sodium hydroxide and/or hydrochloric acid.

Humalog Mix Kwikpen is a premixed (biphasic) insulin analog product combining a crystallized, protamine-complexed form of insulin lispro (which provides an intermediate-acting, delayed-absorption profile) with uncomplexed, rapid-acting insulin lispro (which provides a fast onset of glucose-lowering action). This combination is designed to provide both prandial (mealtime) and basal-like coverage from a single injection.

Insulin lispro itself is a rapid-acting human insulin analog produced by recombinant DNA technology, differing from human insulin by the reversal of the proline and lysine residues at positions B28 and B29, which accelerates its absorption and onset of action compared with regular human insulin.

Humalog Mix Kwikpen is administered subcutaneously and is used as part of a comprehensive treatment plan for diabetes mellitus that includes diet, exercise, and blood glucose monitoring.

Humalog Mix Kwikpen belongs to the therapeutic class of antidiabetic agents, specifically the subclass of premixed (biphasic) insulin analogs, combining an intermediate-acting insulin component with a rapid-acting insulin component in a single formulation.

The primary action of Insulin Lispro Protamine + Insulin Lispro is regulation of glucose metabolism. Like endogenous insulin, insulin lispro lowers blood glucose by:

• Stimulating peripheral glucose uptake by skeletal muscle and adipose tissue.
• Inhibiting hepatic glucose production (gluconeogenesis and glycogenolysis).
• Inhibiting lipolysis and proteolysis, and enhancing protein synthesis.

Pharmacokinetics

This biphasic profile allows Insulin Lispro Protamine + Insulin Lispro to cover both an immediate post-meal glucose rise and a longer background insulin need from a single subcutaneous injection.

Humalog Mix Kwikpen is for subcutaneous injection only, using a syringe or a prefilled/reusable insulin pen as prescribed. Before each injection, resuspend the insulin by gently rolling the vial/pen between the palms and inverting it several times until the suspension appears uniformly cloudy — do not shake vigorously. Inject within 15 minutes before, or immediately after, a meal, rotating injection sites within the abdomen, thigh, upper arm, or buttock. Humalog Mix Kwikpen must not be administered intravenously, intramuscularly, or via an insulin infusion pump, and must not be mixed with other insulins in the same syringe.

Several medicines can alter the blood-glucose-lowering effect of Humalog Mix Kwikpen and change hypoglycemia risk. Clinically significant interactions include:

Any new medication should be reviewed with the prescribing physician, as dose adjustment of Humalog Mix Kwikpen or increased blood glucose monitoring may be needed.

The most common and clinically important adverse effect of Humalog Mix Kwikpen is hypoglycemia, which is discussed fully under Precautions and Warnings and Overdose Effects. Other adverse effects reported with Humalog Mix Kwikpen include:

• Injection-site reactions: pain, redness, swelling, itching, or lipodystrophy (thickening or pitting of fat) at frequently reused injection sites.
• Allergic reactions: localized rash or urticaria at the injection site; rarely, generalized allergic reactions including anaphylaxis.
• Weight gain, associated with the anabolic and glucose-lowering effects of insulin.
• Peripheral edema, particularly on initiation of insulin therapy or with intensified glycemic control.
• Hypokalemia (low blood potassium), particularly if not monitored in at-risk patients.
• Lipodystrophy or cutaneous amyloidosis at injection sites with repeated use at the same location.

Good glycemic control before conception and throughout pregnancy is important for both mother and fetus in women with diabetes. Humalog Mix Kwikpen should be used in pregnancy only under close medical supervision, with insulin requirements individualized and frequently reassessed, as they characteristically change during each trimester and in the postpartum period. Humalog Mix Kwikpen should be used only if clearly needed, and a physician should weigh the potential benefits against potential risks before prescribing it in pregnancy.

Insulin, including insulin lispro, is generally considered compatible with breastfeeding, as it does not appear to pass into breast milk in a way that affects the infant; however, breastfeeding mothers using Humalog Mix Kwikpen may need adjustments to insulin dose and diet, and should remain under medical supervision. A physician should be consulted before use during pregnancy or lactation.

Hypoglycemia

Hypoglycemia is the most common and most serious risk associated with Humalog Mix Kwikpen. It can occur with any insulin therapy and may be caused by too high a dose, delayed or missed meals, unplanned exercise, alcohol intake, or interacting medications. Patients and caregivers should be educated to recognize early warning signs (sweating, tremor, palpitations, confusion) and to always carry a fast-acting source of glucose.

Route and administration errors

Humalog Mix Kwikpen must never be given intravenously or intramuscularly, and must never be used in an insulin pump, as it is a suspension of two insulin fractions with different absorption profiles. Never interchange between different insulin products, brands, concentrations, or premix ratios without explicit medical guidance, since this can result in serious dosing errors leading to severe hypoglycemia or hyperglycemia.

Hypokalemia

Insulin therapy, including Humalog Mix Kwikpen, can cause a shift of potassium into cells, leading to hypokalemia; this may be clinically significant and require monitoring in at-risk patients (e.g. those on potassium-lowering drugs, or with cardiac disease).

Thiazolidinedione co-administration

Patients receiving Humalog Mix Kwikpen together with a thiazolidinedione should be monitored for signs of fluid retention and heart failure; dose reduction or discontinuation of the thiazolidinedione may be required if these occur.

Illness, activity, and dose reassessment

Changes in diet, physical activity, illness, emotional stress, or concurrent medication can affect insulin requirements; dose reassessment by the treating physician is required in these situations.

Injection site rotation

Repeated injection at the same site can cause lipodystrophy or localized amyloidosis, which may alter insulin absorption; injection sites should be rotated systematically.

An overdose of Humalog Mix Kwikpen relative to food intake, physical activity, or concurrent medication can cause hypoglycemia, which may range from mild (hunger, sweating, tremor, palpitations, confusion) to severe (seizures, loss of consciousness).

• Mild-to-moderate hypoglycemia can often be managed by immediately consuming a fast-acting source of oral glucose or sugar, followed by a snack or meal.
• Severe hypoglycemia with loss of consciousness or inability to swallow safely is a medical emergency — seek immediate medical attention or contact emergency services; a caregiver may administer glucagon if trained and available, but professional medical evaluation is still required.
• Prolonged or severe hypoglycemic episodes may require hospitalization for intravenous glucose administration and monitoring.

Do not attempt to manage a severe overdose at home without medical guidance; always contact a physician, hospital, or poison control service.

Unopened (unused) Humalog Mix Kwikpen vials or pens should be stored in a refrigerator (2°C to 8°C), protected from light, and must not be frozen — discard if accidentally frozen. Once a vial or pen is in use, it may generally be kept at room temperature (below 30°C), away from direct heat and light, for the period specified on the product label (commonly up to around 10–28 days depending on the specific product), after which any remaining insulin should be discarded. Always keep Humalog Mix Kwikpen out of the reach of children, and never use it if it looks clumped, frosted, discolored, or contains particles after resuspension.

Pediatric patients

Safety and efficacy of Humalog Mix Kwikpen in children have not been well established; use in pediatric patients requires specialist supervision (see Pediatric Uses).

Elderly patients

Elderly patients may be more sensitive to the glucose-lowering effects of Humalog Mix Kwikpen and may have reduced ability to recognize hypoglycemia symptoms. A conservative initial dose with careful titration and closer monitoring is recommended.

Renal impairment

Insulin clearance may be reduced in renal impairment, increasing the risk of hypoglycemia; dose reduction and more frequent glucose monitoring are recommended.

Hepatic impairment

Reduced hepatic gluconeogenesis and slower insulin metabolism in hepatic impairment may lower insulin requirements; closer monitoring is advised.

Pregnancy and lactation

See Pregnancy and Lactation section for detailed guidance.

Humalog Mix Kwikpen is generally used as a long-term, often lifelong, component of diabetes management in patients who require insulin therapy, since diabetes mellitus is a chronic condition. The dose and regimen (not the underlying need for insulin) are reviewed and adjusted periodically by the treating physician based on glycemic control (e.g. HbA1c), body weight changes, and clinical status; therapy should not be stopped or the regimen changed without medical advice.

Insulin Lispro Protamine + Insulin Lispro belongs to the drug class of insulins, specifically premixed (biphasic) insulin analog combinations, pairing an intermediate-acting insulin (insulin lispro protamine suspension) with a rapid-acting insulin analog (insulin lispro).

Insulin Lispro Protamine + Insulin Lispro works by supplying exogenous insulin that binds to insulin receptors on target cells (primarily in muscle, liver, and adipose tissue), triggering translocation of glucose transporters (GLUT4) to the cell surface and thereby promoting cellular glucose uptake, while simultaneously suppressing hepatic glucose output and inhibiting lipolysis. The protamine-complexed fraction dissolves slowly at the injection site, providing a delayed, intermediate-acting release of insulin lispro, while the uncomplexed fraction is absorbed rapidly, providing a fast onset of action to cover the glucose rise after a meal.

B

The safety and effectiveness of Humalog Mix Kwikpen in pediatric patients have not been well established in controlled clinical trials, and its use in children should only be undertaken under the supervision of a pediatric endocrinologist or specialist experienced in managing diabetes in children. If used, dosing must be individualized based on body weight, meal pattern, and frequent blood glucose monitoring, with particular attention to the increased risk of hypoglycemia and its potential effects on a child's cognitive development. Parents/caregivers should be thoroughly trained in glucose monitoring and hypoglycemia recognition and management before Humalog Mix Kwikpen is used in a child.